- Home
- PHAT vs CFFN Comparison
PHAT vs CFFN Comparison
Compare PHAT & CFFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAT | CFFN |
|---|---|---|
| Founded | 2018 | 1893 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 905.3M |
| IPO Year | 2019 | 1999 |
Fundamental Metrics
Financial Performance| Metric | PHAT | CFFN |
|---|---|---|
| Price | $12.78 | $7.58 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $17.33 | $7.25 |
| AVG Volume (30 Days) | ★ 1.1M | 1.1M |
| Earning Date | 03-05-2026 | 01-28-2026 |
| Dividend Yield | N/A | ★ 4.47% |
| EPS Growth | N/A | ★ 42.90 |
| EPS | N/A | ★ 0.56 |
| Revenue | $147,190,000.00 | ★ $209,735,000.00 |
| Revenue This Year | $221.87 | $17.43 |
| Revenue Next Year | $80.37 | $9.10 |
| P/E Ratio | ★ N/A | $13.58 |
| Revenue Growth | ★ 460.30 | 15.42 |
| 52 Week Low | $2.21 | $4.90 |
| 52 Week High | $18.31 | $7.74 |
Technical Indicators
Market Signals| Indicator | PHAT | CFFN |
|---|---|---|
| Relative Strength Index (RSI) | 38.22 | 68.96 |
| Support Level | $12.22 | $7.53 |
| Resistance Level | $14.53 | $7.40 |
| Average True Range (ATR) | 0.85 | 0.24 |
| MACD | -0.12 | 0.06 |
| Stochastic Oscillator | 23.22 | 83.49 |
Price Performance
Historical ComparisonAbout PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About CFFN Capitol Federal Financial Inc.
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.